TG Therapeutics' strong cash position and Briumvi success fuel growth potential. Find out why TGTX stock is rated a strong ...

TG Therapeutics' financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite ...

生物技术公司 TG Therapeutics（TGTX） 股票在公布超出预期的第四财季业绩后，成为投资者追捧的热门对象。根据标普全球市场情报汇编的数据，截至周五（3月7日）下午，该公司的股价自本周以来已上涨近27%。

TG Therapeutics (TGTX) stock surged 17% on Mar. 3 after the company reported revenue that topped Wall Street estimates. The company reported Q4 earnings per share of 15 cents, falling short of the ...

TG Therapeutics, Inc. has announced its schedule for presenting data on BRIUMVI® (ublituximab-xiiy) at the upcoming American Academy of Neurology 2025 annual meeting in San Diego, California ...

Doctors prescribe Briumvi (ublituximab-xiiy) for certain forms of multiple sclerosis (MS). You’ll receive infusions (into your vein) over a period of months. Before each infusion, you’ll ...

Following news of an estimates-topping fourth quarter, TG Therapeutics (NASDAQ: TGTX) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market ...

TG Therapeutics will present data on BRIUMVI for relapsing multiple sclerosis at the ACTRIMS forum, February 27 – March 1, 2025. TG Therapeutics, Inc. announced the schedule for presentations on ...

TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price ...

TG Therapeutics (NasdaqCM:TGTX) saw its share price surge by 28% last week following a robust earnings announcement. The company's fourth-quarter revenue grew by 146% year-over-year, accompanied by a ...

Reports Q4 revenue $108.185M, consensus $100.67M. Michael Weiss, the Company’s Chairman and Chief Executive Officer, stated, “2024 was a year ...